Takeda Ventures
Takeda Ventures focuses on high-caliber therapeutic and platform based opportunities around the world.
Business Model:
Revenue: $30.4B
Employees: 10,001-999,999
Rankings
Industries / Tags:
Detailed Takeda Ventures Information
Geographic Data
Address: 1-1, Nihonbashi-Honcho 2-chome
City: Tokyo
State: tōkyō prefecture
Zip: 103-8668
Country: JP
Financial Info
Stage:
Raised Last:
$0
Raised Total:$8B
Social
Twitter
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Takeda Ventures, Inc. (TVI) is the corporate investment arm of Takeda Pharmaceutical Company Limited (TPC). TVI was founded in 2001 and invests in current and future areas of interest for TPC. We are based alongside Takeda’s R&a;D sites in Cambridge, MA, and San Diego, CA. As a strategic investor, TVI aims to provide support and guidance to entrepreneurs and early-stage companies driving concepts through clinical proof of concept. We also strive to forge active, collaborative interactions that result in synergies with Takeda&s;s considerable R&a;D resources. Our goal is to build a portfolio of strategic investments, with an immediate emphasis on oncology, gastroenterology, neuroscience, and rare diseases.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 1/2006 | Symphogen | Series D | 0 |
| 4/2022 | Be Biopharma | Series B | 0 |
| 1/2016 | Cortexyme | Series A | 15M |
| 4/2021 | Code Biotherapeutics | Seed Round | 0 |
| 9/2014 | BioMotiv | Venture Round | 25M |
| 4/2020 | Cerevance | Series B | 65M |
| 2/2010 | Domainex | Venture Round | - |
| 5/2017 | BIOMx | Series A | 24M |
| 4/2018 | Crescendo Biologics | Series B | 0 |
| 12/2016 | Hookipa Pharma | Series B | 10.7M |
| 1/2020 | Transine Therapeutics | Seed Round | - |
| 11/2017 | Outpost Medicine, LLC | Series A | 20M |
| 2/2021 | Xilio Therapeutics | Series C | 95M |
| 6/2018 | StrideBio | Series A | 15.7M |
| 10/2018 | Bsense Bio Therapeutics | Seed Round | 405k |
| 12/2014 | Naurex | Series C | 0 |
| 10/2005 | Serenex | Series C | 30M |
| 3/2021 | Presage Biosciences | Convertible Note | 6M |
| 11/2022 | hC Bioscience | Series A | 0 |
| 1/2020 | Emendo Biotherapeutics | Series B | 61M |
| 5/2020 | Amwell | Series C | 0 |
| 11/2019 | Protekt Therapeutics | Venture Round | 4.1M |
| 12/2013 | VHSquared | Series A | - |
| 6/2007 | Serenex | Series D | 0 |
| 5/2017 | OrphoMed | Series A | 39M |
| 10/2017 | Portal Instruments | Venture Round | 6M |
| 7/2012 | Juventas Therapeutics | Series B | 0 |
| 2/2019 | Hookipa Pharma | Series D | 37.4M |
| 2/2022 | Koneksa Health | Series C | 0 |
| 5/2021 | BridGene Biosciences | Series A | 0 |
| 1/2020 | EvolveImmune Therapeutics | Venture Round | 17.5M |
| 4/2021 | Adaptate Biotherapeutics | Series A | 18.2M |
| 10/2020 | Be Biopharma | Series A | 52M |
| 9/2018 | Ramino Bio | Seed Round | - |
| 10/2019 | Arcellx | Series B | 0 |
| 8/2020 | ImmPACT Bio | Series A | 0 |
| 2/2021 | Ensoma | Series A | 0 |
| 9/2020 | Palleon Pharmaceuticals | Series B | 100M |
| 2/2023 | Cerevance | Series B | 0 |
| 11/2013 | Hookipa Pharma | Series B | 27M |
| 6/2016 | Ultragenyx Pharmaceutical | Post-IPO Equity | 65M |
| 6/2022 | Code Biotherapeutics | Series A | 0 |
| 2/2022 | hC Bioscience | Series A | 0 |
| 8/2018 | Ambys Medicines | Series A | 60M |
| 11/2012 | ArmaGen Technologies | Series A | 0 |
| 3/2021 | StrideBio | Series B | 0 |
| 5/2018 | Cortexyme | Series B | 76M |
| 3/2020 | Redpin Therapeutics | Series A | 15.5M |
| 6/2011 | Redwood Bioscience | Venture Round | - |
| 12/2017 | Hookipa Pharma | Series C | 0 |
| 8/2016 | Bioniz Therapeutics | Series A | 0 |
| 5/2011 | Naurex | Series A | 18M |
| 6/2013 | Heptares Therapeutics | Series B | 0 |
| 10/2017 | Palleon Pharmaceuticals | Series A | 47.6M |
| 4/2005 | Receptor Biologix | Series A | 33.6M |
| 11/2020 | Catamaran Bio | Series A | 0 |
| 7/2018 | Presage Biosciences | Series D | 6M |
| 5/2023 | OncoResponse | Venture Round | 0 |
| 1/2023 | Ensoma | Series B | 0 |
| 1/2019 | Ribon Therapeutics | Series B | 65M |
| 10/2009 | Envoy Therapeutics | Series A | 8M |
| 8/2015 | Presage Biosciences | Venture Round | - |
| 4/2017 | Cortexyme | Debt Financing | 8M |
| 7/2018 | ARTham Therapeutics | Series A | - |
| 1/2018 | SEEDSUPPLY | Seed Round | - |
| 2/2006 | Lectus Therapeutics | Series A | 14.3M |
| 10/2018 | VelosBio | Series A | 58M |
| 10/2021 | Egle Therapeutics | Series A | 0 |
| 6/2021 | Transine Therapeutics | Seed Round | 0 |
| 10/2007 | CellCentric | Venture Round | 4.3M |
| 5/2023 | Larkspur Biosciences | Series A | 0 |
| 1/2021 | Aspen RxHealth | Series B | 23M |
| 7/2004 | Serenex | Venture Round | 8M |
| 3/2020 | Xilio Therapeutics | Series B | 100.5M |
| 7/2021 | Turnstone Biologics | Series D | 0 |
| 7/2020 | VelosBio | Series B | 137M |
| 6/2021 | Ribon Therapeutics | Series C | 0 |
| 12/2015 | Prosetta Biosciences | Series D | 31M |
| 12/2021 | Integra Therapeutics | Seed Round | 0 |
| 11/2019 | Avidity Biosciences | Series C | 0 |
| 2/2018 | Wave Life Sciences | Post-IPO Equity | 60M |
| 9/2015 | Encycle Therapeutics | Venture Round | 0 |
| 2/2019 | BIOMx | Series B | 0 |
| 8/2022 | Zelluna Immunotherapy | Venture Round | - |
| 11/2022 | Enzyre | Series A | 0 |
| 12/2017 | Obsidian Therapeutics | Series A | 0 |
| 3/2011 | CellCentric | Series B | - |
| 5/2017 | GammaDelta Therapeutics | Venture Round | 100M |
| 11/2018 | Axcelead | Seed Round | - |
| 5/2019 | Phathom Pharmaceuticals | Private Equity Round | 90M |
| 5/2023 | Larkspur Biosciences | Series A | 0 |
| 5/2023 | OncoResponse | Venture Round | 0 |
| 2/2023 | Cerevance | Series B | 0 |
| 1/2023 | Ensoma | Series B | 0 |
| 11/2022 | hC Bioscience | Series A | 0 |
| 11/2022 | Enzyre | Series A | 0 |
| 8/2022 | Zelluna Immunotherapy | Venture Round | - |
| 6/2022 | Code Biotherapeutics | Series A | 0 |
| 4/2022 | Be Biopharma | Series B | 0 |
| 2/2022 | hC Bioscience | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
